Caris Life Sciences (CAI) Stock Price
Caris Life Sciences Price
Revenue has compounded at 13.8% per year over the past 20 years to 812.03 M USD. Earnings per share have grown at 29.0% per year over the last 15 years. Caris Life Sciences's net margin stands at -66.2%, down from 9.4% several years earlier. Caris Life Sciences currently offers a dividend yield of about 5.12%. The payout ratio is around 32% of earnings. Analysts set a median price target of 38.00 USD, implying 116.2% above the current price. Of 16 analysts, 12 rate the stock a buy — an overall Buy consensus.
Caris Life Sciences stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Caris Life Sciences business model & stock analysis
Frequently asked questions about Caris Life Sciences
Analysts currently set an average price target of 34.00 USD for the Caris Life Sciences stock (median: 38.00 USD), implying +93.4 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Caris Life Sciences stock: 12 recommend buying, 4 holding and 0 selling. For 2026, analysts expect Caris Life Sciences to generate revenue of 1.04 B USD and earnings per share of 0.11 USD.
Converted at the current exchange rate, the Caris Life Sciences share trades at 16.02 EUR (17.58 USD).
The Caris Life Sciences share (CAI) is listed on 1 stock exchanges, including: NYSE (CAI).
The expected revenue of Caris Life Sciences is 1.04 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Caris Life Sciences is 31.95 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Caris Life Sciences is currently 159.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Caris Life Sciences stock.
The price-to-sales ratio (P/S) of Caris Life Sciences is currently 4.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Caris Life Sciences stock.
The Eulerpool Quality Score for Caris Life Sciences is 5/10.
The ISIN of Caris Life Sciences is US1421521071. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Caris Life Sciences is A0MLRM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Caris Life Sciences is CAI. The ticker symbol is used to trade Caris Life Sciences shares on the stock exchange.
Caris Life Sciences stock
Caris Life Sciences Peer Group
Caris Life Sciences Ticker
All fundamentals and in-depth analysis of Caris Life Sciences
Our stock analysis for Caris Life Sciences stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Caris Life Sciences. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.